

Kauffman Michael
Form 4
July 20, 2018

FORM 4

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Kauffman Michael

2. Issuer Name **and** Ticker or Trading
Symbol
Karyopharm Therapeutics Inc.
[KPTI]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)
C/O KARYOPHARM
THERAPEUTICS INC., 85 WELLS
AVENUE

3. Date of Earliest Transaction
(Month/Day/Year)
07/18/2018

☒ Director ☐ 10% Owner
☒ Officer (give title below) ☐ Other (specify below)
Chief Executive Officer

(Street)
NEWTON, MA 02459

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
☒ Form filed by One Reporting Person
☐ Form filed by More than One Reporting
Person

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price		
Common Stock	07/18/2018		M ⁽¹⁾	1	A	\$ 0.033	512,144	D	
Common Stock	07/18/2018		M ⁽¹⁾	5,757	A	\$ 0.264	517,901	D	
Common Stock	07/18/2018		M ⁽¹⁾	4,242	A	\$ 4.752	522,143	D	
Common Stock	07/18/2018		S ⁽¹⁾	10,000	D	\$ 18.2686 (2)	512,143	D	

Edgar Filing: Kauffman Michael - Form 4

Common Stock	713,510	I	By Spouse
Common Stock	47,309	I	By GRAT ⁽³⁾
Common Stock	47,309	I	By Spouse's GRAT ⁽⁴⁾

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Deemed Exercise Date (Instr. 3 and 4)		
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 0.033	07/18/2018		M ⁽¹⁾		1		⁽⁵⁾	12/31/2020	Common Stock	1
Stock Option (right to buy)	\$ 0.264	07/18/2018		M ⁽¹⁾		5,757		⁽⁶⁾	12/13/2021	Common Stock	5,757
Stock Option (right to buy)	\$ 4.752	07/18/2018		M ⁽¹⁾		4,242		⁽⁷⁾	09/02/2023	Common Stock	4,242

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Kauffman Michael
C/O KARYOPHARM THERAPEUTICS INC.
85 WELLS AVENUE
NEWTON, MA 02459

X

Chief Executive Officer

Signatures

/s/ Christopher B. Primiano, Attorney-in-Fact for Michael G.
Kauffman

07/20/2018

__Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from \$18.00 to \$18.50, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (3) These shares are held by the Michael G. Kauffman 2016 Qualified Annuity Interest Trust.
- (4) These shares are held by the Sharon Shacham 2016 Qualified Annuity Interest Trust.
- (5) This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on January 1, 2012, and the remaining 75% vested in 36 equal monthly installments thereafter.
- (6) This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on June 18, 2013, and the remaining 75% vested in 36 equal monthly installments thereafter.
- (7) This option, representing a right to purchase a specified number of shares, vested as to 25% of the shares on September 3, 2014, and the remaining 75% vested in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.